Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Insulin receptor-mediated cell-specific effects of GLP-1 receptor agonists in mouse model of restenosis

EF 2023-24

Résumé
Atherosclerosis is the leading cause of mortality via cardiovascular diseases. One of its treatments include percutaneous transluminal coronary angioplasty, in-stent procedure to reduce vessel blockage. Such processes could cause restenosis, an acute repair process in response to injury. Although drug-eluting stents have decreased occurrence of restenosis, those with type-2 diabetes remain at risk. Our lab found that exogenous insulin has an anti-restenotic effect in murine models of restenosis (femoral-artery injury). This is abolished in mice endothelial (EC) and vascular smooth muscle (VSMC) cell insulin receptor (IR) knockouts fed with low-fat diet (LFD). However, there is no change in similar mice fed high-fat diet (HFSD). This may be due to insulin resistance. Therefore, we hypothesize that GLP-1 receptor agonists (liraglutide), which increase insulin secretion and have shown vasculoprotective effects mediated by endothelial nitric-oxide synthase (eNOS) like insulin will maintain IR-mediated protective effects, through insulin, on restenosis in HFSD mice. We will use tamoxifen-induced EC- and VSMC-specific IR knockout mice models of restenosis. Liraglutide will be used to see how neointimal growth (restenosis marker) changes. We hypothesize that wild-type mice fed on LFD and HFSD will show decrease in neointimal growth, whereas this effect will be abolished in both IR knockout mice irrespective of diet.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
505920
Name
Chaudhry Talha A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Insulin receptor-mediated cell-specific effects of GLP-1 receptor agonists in mouse model of restenosis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atherosclerosis; Endothelial Cells; Femoral Artery Injury; Glp-1-Like Agonists (Liraglutide); Insulin; Insulin Receptor; Insulin Resistance; Restenosis; Type 2 Diabetes Mellitus; Vascular Smooth Muscle Celles
Abstract
Atherosclerosis is the leading cause of mortality via cardiovascular diseases. One of its treatments include percutaneous transluminal coronary angioplasty, in-stent procedure to reduce vessel blockage. Such processes could cause restenosis, an acute repair process in response to injury. Although drug-eluting stents have decreased occurrence of restenosis, those with type-2 diabetes remain at risk. Our lab found that exogenous insulin has an anti-restenotic effect in murine models of restenosis (femoral-artery injury). This is abolished in mice endothelial (EC) and vascular smooth muscle (VSMC) cell insulin receptor (IR) knockouts fed with low-fat diet (LFD). However, there is no change in similar mice fed high-fat diet (HFSD). This may be due to insulin resistance. Therefore, we hypothesize that GLP-1 receptor agonists (liraglutide), which increase insulin secretion and have shown vasculoprotective effects mediated by endothelial nitric-oxide synthase (eNOS) like insulin will maintain IR-mediated protective effects, through insulin, on restenosis in HFSD mice. We will use tamoxifen-induced EC- and VSMC-specific IR knockout mice models of restenosis. Liraglutide will be used to see how neointimal growth (restenosis marker) changes. We hypothesize that wild-type mice fed on LFD and HFSD will show decrease in neointimal growth, whereas this effect will be abolished in both IR knockout mice irrespective of diet.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chaudhry, Talha A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~